| Safarzadeh M., et al., 2016 |
Iran |
Group A:
Male- 19
Female- 22
Group B:
Male- 21
Female- 26 |
Dry eye patients
41 in Group A
47 in Group B |
Tear Naturale (Alcon): dextran 70 -1 mg/ml, hypromellose 3 mg/ml, hydroxipropyl, metylcellulose, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, zinc chloride, sodiumhydrogen carbonate, carbono dioxide, purified water (non-preservative) |
Tearlose (Darou Company)
Hydroxipropyl, methylcellulose
0.3 g, 0.1 g of dextran hydroxipropyl and 0.01% benzalkonium chloride as preservative |
a) OSDI scale of symptoms
b) Rate of tear secretion-Schirmer test
c) Rate of tear evaporation - TFBUT
d) Staining in córnea
e) conjunctival staining |
Group A:
OSDI: 43.58 baseline,
31.92 after 4 weeks,
(P<0.001)
TFBUT
baseline: 7 seg, and after
4 weeks: 7.62 (P=0.027)
Conjunctival score:
baseline: 6.67 and after
4 weeks: 5.53 (P<0.001)
Corneal staining
baseline:1.23 and after
4 weeks-0.44 (P<0.001)
Schirmer:
baseline 6.04 and after
4 weeks-6.56 (P=0.129) |
Group B:
OSDI: 39.51 baseline,
29.97 after 4 weeks,
(P<0.001)
TFBUT
baseline: 7.15 seg, and after 4 weeks: 8.09 (P=0.013)
Conjunctival score:
baseline: 7.34 and after
4 weeks: 5.09 (P<0.001)
Corneal score
baseline:1.15 Schirmer:
baseline 6.64 and after
4 weeks-7.10 (P=0.115) |
Baseline:
OSDI: P=0.339
TFBUT: P=0.640
Conjunctival staining: P=0.334
Corneal staining: P=0.807
Schirmer: P=0.676
after 4 weeks:
OSDI: P=0.440
TFBUT: P=0.497
Conjunctival staining: P=0.822
Corneal staining: P=0.793
Schirmer: P=0.441 |
|
| Perez-Balbuena AL, et al., 2016 |
Mexico |
Information about the multicenters are not compiled |
Mild to moderate dry eye patients
76 in Group XG/CS
72 in Group PEG/PG |
Xiel Ofteno -Sophia laboratories (0,09% xanthan gum/0,1% chondroitin sulfate preservative-free) |
Systane-Alcon
(polyethylene glycol/propylene glycol) |
a) OSDI scale of symptoms
b) Rate of tear secretion tax- Schirmer test
c) Rate of tear evaporation - TFBUT
d) corneal staining
e) conjunctival staining |
Group A OR XG/CS:
OSDI 19.3 baseline, 7.3 after
8 weeks (P=0.001)
Schirmer: 6.4baseline, 11.0 after 8 weeks, (P=0.002)
TBUT: baseline-5.5, 7.4 after 8 weeks
(P=0.027) |
Group B OR
PEG/PG
OSDI: 19,3 baseline, 7.9 after 8 weeks (P=0.001)
Schirmer: 6.5baseline, 10.5 after 8 weeks, (P=0.019)
TBUT: 5.2baseline, 7.4, after 8 weeks (P=0.046) |
Says that is not statistically significant but do not say p's value |
- Do not say the P between the two groups
- Refers to "staining" as a variable but do not says these results
- Informatiosn about gender are not compiled |
| Nelson, JD, et al., 1988 |
U.S.A |
Sodium hyaluronate (HS) Group: Male- 3
Female- 17
Polyvinyl alcohhol (PVA):
Male- 1
Female- 14 |
Severe dry eye
20 in HS Group
15 in PVA Group |
Pharmacia - Piscataway, NJ
(unpreserved 0,1% sodium hyaluronic purified water) |
Liquifilm - Allergan
(1,4% polyvinyl alcohool with chlorabutanol 0,5%) |
a) Tear osmolarity
b) Pain/analog scale
c) Patients comments (symptoms)
d) Eye drops frequency of use
e) Visual acuity
f) Rate of tear evaporation -TFBUT
g) Rose bengal staining
h) Rate of tear secretion- schirmer test
i) Ocular surface impression citology |
Group A OR HS Group:
a) Pain scale
65.9 baseline, 37.0 after
8 weeks
b) Tear osmolarity
339.5 baseline, 312.0 after
8 weeks
c) Schirmer
5.1 baseline, 6.5 after 8 weeks
d) TFBUT
3.5 baseline, 4.9 after 8 weeks
e) Rose bengal staining
4.0 baseline, 2.8 after 8 weeks
f) Bulbar and palpebral
impression citology
Bulbar:
2.4 baseline, 2.3 after 8 weeks
Palpebral:
1.3 baseline, 0.8 after 8 weeks |
Group B OR PVA Group
a) Pain scale
67.6 baseline, 31.3 after
8 weeks
b) tear osmolarity
371.4 baseline, 311.6 after
8 weeks
c) Schirmer
5.3 baseline, 6.6 after
8 weeks
d)TFBUT
4.8 baseline, 6.3 after weeks
e) Rose bengal staining
3.1 baseline, 2.3 after
8 weeks
f) Bulbar and palpebral
impression citology
Bulbar:
2.7 baseline, 2.3 after
8 weeks
Palpebral:
1.0 baseline, 0.7 after
8 weeks |
Says that is not statistically significant but do not say p's value |
- Do not say the P between the two groups
- Not detailed description of the variabels (visual acuity, frequency of use, symptoms comments) |
| Astakhov, YS et al., 2013 |
Russia |
Hylabak Group: Male- 11
Female- 16
Systane Group: Male- 11
Female- 16 |
Mild dry eye after LASIK surgery
27 in HYLABAK Group
25 in SYSTANE Group |
Intervention:
Hylabak, Abak, THEA Laboratories, (0,15% hyaluronato preservative -free) |
CONTROL
Systane, Alcon
(polyethylene glycol 0,4%, propylene glycol 0,3%, polidronium chloride 0,001% as preservative) |
a) Drymess
b) Fluorescein satining
c) Global tolerance
d) Global efficacy and tolerance- investigator
e) Best corrected visual acuity
f) Rate of tear evaporation- TFBUT
g) Lid-paralel conjunctival folds- lipcof test
h) Slit lamp acessment- as blepharitis and meibomitis |
HYLABAK Group
a) Dryness - no patients after 84 days
b) Fluorescein staining-0.26 baseline, 0.11 after 12 weeks (P=0.16)
c) Global efficacy and tolerance- investigator-one case "not satisfactory," 62.96% "very satisfactory"
d) Best corrected visual acuity
59.26% had 6/6 in baseline, 81.48% had 6/6 after 12 weeks
e) TFBUT-just describes p<0.0001, between baseline and after 12 weeks
f) Lid-paralel conjunctival folds- lipcof test
baseline: 55.56% no
paralell fold
40.74% one parallel fold
1 severe parallel fold
after 12 weeks: 81.48% no parallel fold, none severe parallel fold
g) Slit lamp acessment -
as blepharitis, meibomitis and flap edema
baseline: flap edema -2 (7,41%) No one in day 84.
after 12 weeks: One (3,7%)
had flap folds |
SYSTANE Group
a) Dryness - after 12 weeks: no patients
b) Fluorescein staining- 0.11 baseline, 0.16
after 12 weeks
(P=0.03)
c) Global efficacy and tolerance- investigator- 37.04% "very satisfactory"
d) Best corrected visual acuity
64% had 6/6 in baseline, 84% had 6/6 after 12 weeks
e) TFBUT-just describes p<0.0001, between baseline and after 12 weeks
f) Lid-paralel conjunctival folds- lipcof test
baseline: 64% no paralell fold
24% one parallel fold
1 severe parallel fold
after 12 weeks: 88% no parallel fold
None severe parallel fold
g) Slit lamp acessment- as blepharitis, meibomitis, and flap edema-
baseline: 1 (4%) after
12 weeks:
No one |
Says that is not statistically significant but do not say p's value
Just statistically significant in 28 day in "global efficacy" to hylabak (P=0.0113) |
- Do not say the P between the two groups
- No detailed description of the variabels (TBUT, symptoms, global tolerance scale.
- Use of collors design graphics scales without exact numbers |
